These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 14575967)

  • 1. Fulvestrant: spreading the word, but not too thinly.
    Wilcken NR; Stockler MR
    Lancet; 2003 Oct; 362(9392):1254. PubMed ID: 14575967
    [No Abstract]   [Full Text] [Related]  

  • 2. Fulvestrant (Faslodex): current status in the therapy of breast cancer.
    Bundred N; Howell A
    Expert Rev Anticancer Ther; 2002 Apr; 2(2):151-60. PubMed ID: 12113237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Fulvestrant].
    Roth S; Schaad S; Hardel V; Jaehde U
    Dtsch Med Wochenschr; 2006 Dec; 131(48):2718-21. PubMed ID: 17123238
    [No Abstract]   [Full Text] [Related]  

  • 4. Fulvestrant antiestrogen for treatment of breast cancer.
    Hancock CM
    Clin J Oncol Nurs; 2003; 7(2):201-2. PubMed ID: 12696217
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is fulvestrant more effective than tamoxifen for treating ER-positive breast cancer in postmenopausal women?
    Raina V
    Nat Clin Pract Oncol; 2004 Nov; 1(1):20-1. PubMed ID: 16264793
    [No Abstract]   [Full Text] [Related]  

  • 6. Emerging data on the efficacy and safety of fulvestrant, a unique antiestrogen therapy for advanced breast cancer.
    Scott SM; Brown M; Come SE
    Expert Opin Drug Saf; 2011 Sep; 10(5):819-26. PubMed ID: 21699443
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials.
    Robertson JF; Osborne CK; Howell A; Jones SE; Mauriac L; Ellis M; Kleeberg UR; Come SE; Vergote I; Gertler S; Buzdar A; Webster A; Morris C
    Cancer; 2003 Jul; 98(2):229-38. PubMed ID: 12872340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fulvestrant ('Faslodex'): extending the reach of endocrine therapy?
    Johnston SR
    Breast Cancer Res Treat; 2005; 93 Suppl 1():S1-2. PubMed ID: 16247593
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fulvestrant is an effective and well-tolerated endocrine therapy for postmenopausal women with advanced breast cancer: results from clinical trials.
    Vergote I; Robertson JF
    Br J Cancer; 2004 Mar; 90 Suppl 1(Suppl 1):S11-4. PubMed ID: 15094759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TAS-108: a novel steroidal antiestrogen.
    Buzdar AU
    Clin Cancer Res; 2005 Jan; 11(2 Pt 2):906s-8s. PubMed ID: 15701885
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Misperception of estrogen activity in patients treated with an estrogen receptor antagonist.
    Elguero S; Patel B; Liu JH
    Am J Obstet Gynecol; 2014 Sep; 211(3):e1-2. PubMed ID: 24881832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fulvestrant in women with advanced breast cancer after progression on prior aromatase inhibitor therapy: North Central Cancer Treatment Group Trial N0032.
    Ingle JN; Suman VJ; Rowland KM; Mirchandani D; Bernath AM; Camoriano JK; Fishkin PA; Nikcevich DA; Perez EA;
    J Clin Oncol; 2006 Mar; 24(7):1052-6. PubMed ID: 16505423
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fulvestrant revisited: efficacy and safety of the 500-mg dose.
    Howell A; Sapunar F
    Clin Breast Cancer; 2011 Aug; 11(4):204-10. PubMed ID: 21729658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endocrine response after prior treatment with fulvestrant in postmenopausal women with advanced breast cancer: experience from a single centre.
    Cheung KL; Owers R; Robertson JF
    Endocr Relat Cancer; 2006 Mar; 13(1):251-5. PubMed ID: 16601292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fulvestrant: pharmacologic profile versus existing endocrine agents for the treatment of breast cancer.
    Buzdar AU; Robertson JF
    Ann Pharmacother; 2006 Sep; 40(9):1572-83. PubMed ID: 16912252
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endocrine therapy for the treatment of postmenopausal women with breast cancer.
    Harichand-Herdt S; Zelnak A; O'Regan R
    Expert Rev Anticancer Ther; 2009 Feb; 9(2):187-98. PubMed ID: 19192957
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Time to response: comparison of fulvestrant and oral endocrine agents.
    Dodwell D; Pippen J
    Clin Breast Cancer; 2006 Aug; 7(3):244-7. PubMed ID: 16942641
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical use of selective estrogen receptor modulators and down regulators with the main focus on breast cancer.
    Baumann CK; Castiglione-Gertsch M
    Minerva Ginecol; 2009 Dec; 61(6):517-39. PubMed ID: 19942839
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fulvestrant for the treatment of advanced breast cancer in postmenopausal women: a Japanese study.
    Watanabe T; Sano M; Ohno S; Inaji H; Nishimura R; Shin E; Nomura Y; Morris C
    Anticancer Res; 2004; 24(2C):1275-80. PubMed ID: 15154660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Postmenopausal advanced breast cancer: options for therapy after tamoxifen and aromatase inhibitors.
    Dodwell D; Wardley A; Johnston S
    Breast; 2006 Oct; 15(5):584-94. PubMed ID: 16504510
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.